<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972842</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_PTCL1</org_study_id>
    <secondary_id>EudraCT 2008-006919-20</secondary_id>
    <nct_id>NCT00972842</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)</brief_title>
  <acronym>LenVoDex</acronym>
  <official_title>Phase I/II Trial of Lenalidomide in Combination With Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A standard therapy is neither established in first-line patients nor in relapsed patients&#xD;
      with PTCL, and there is still an unmet medical need to identify novel efficacious and safe&#xD;
      therapy regimens.&#xD;
&#xD;
      The aim of this study is to evaluate the potential of a Lenalidomide plus Vorinostat and&#xD;
      Dexamethasone combination therapy as an effective and safe therapeutic regimen, in the&#xD;
      treatment of relapsed PTCL following failure of prior regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to determine the maximum tolerated dose (MTD) of a Lenalidomide, Vorinostat, and Dexamethasone combination regimen in terms of occurrence of dose-limiting toxicities (DLT) at any dose level.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate of a combination therapy with Lenalidomide, Vorinostat, and Dexamethasone in a treatment refractory or relapsed population, defined as the percentage of patients achieving a complete response (CR) or partial response (PR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peripheral T-Cell Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat, Lenalidomide</intervention_name>
    <description>Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles&#xD;
Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles</description>
    <other_name>Revlimid®</other_name>
    <other_name>Zolinza®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsed PTCL according to WHO criteria who have received max. two&#xD;
             previous treatments for PTCL&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Adequate bone marrow function i.e. absolute neutrophile count of &gt; 1000/µl and&#xD;
             thrombocytes &gt; 75,000/µl.&#xD;
&#xD;
          -  Alkaline phosphatase and transaminases ≤ 2,5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 2,5 x ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
          -  Female subjects of childbearing potential† must: Understand that the study medication&#xD;
             could have an expected teratogenic risk and agree to use, and be able to comply with,&#xD;
             effective contraception and agree to have a medically supervised pregnancy test&#xD;
&#xD;
          -  Male subjects must agree to use condoms and agree not to donate semen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of malignancies, other than PTCL, unless the subject has been free of&#xD;
             the disease for ≥ 3 years&#xD;
&#xD;
          -  Prior allogeneic bone marrow transplant or plans to undergo autologous/ allogeneic&#xD;
             bone marrow transplant within 4 weeks of the initiation of vorinostat administration&#xD;
&#xD;
          -  Prior treatment with a HDAC inhibitor&#xD;
&#xD;
          -  Prior treatment with Lenalidomide (patients previously treated with Thalidomide may be&#xD;
             enrolled)&#xD;
&#xD;
          -  Known history of Deep Vein Thrombosis (DVT) and/ or pulmonary embolism (PE)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Hopfinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanusch Krankenhaus Wien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>September 7, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>December 23, 2013</last_update_submitted>
  <last_update_submitted_qc>December 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTCL</keyword>
  <keyword>Peripheral T-Cell Non-Hodgkin's Lymphoma</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>Lenalidomid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

